STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in	1
		the title or the abstract	
		(b) Provide in the abstract an informative and balanced	2-3
		summary of what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the	4-5
		investigation being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5-7
Setting	5	Describe the setting, locations, and relevant dates, including	6-7
		periods of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of	6-7
		selection of participants. Describe methods of follow-up	
		(b) For matched studies, give matching criteria and number of	N/A
		exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential	7-9
		confounders, and effect modifiers. Give diagnostic criteria, if	
		applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of	7-9
measurement		methods of assessment (measurement). Describe comparability	
		of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	6-9
Study size	10	Explain how the study size was arrived at	N/A
Quantitative	11	Explain how quantitative variables were handled in the	6-9
variables Statistical mathods		analyses. If applicable, describe which groupings were chosen	
	42	and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to	6-9
		control for confounding	
		(b) Describe any methods used to examine subgroups and	6-9
		interactions (a) Explain how missing data were addressed	NI/A
		(c) Explain how missing data were addressed	N/A
		(d) If applicable, explain how loss to follow-up was addressed	N/A
		(<u>e</u>) Describe any sensitivity analyses	N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg	10
		numbers potentially eligible, examined for eligibility, confirmed	
		eligible, included in the study, completing follow-up, and	
		(h) Give reasons for non-participation at each stage	NI/A
		(b) Give reasons for non-participation at each stage	N/A
Docarintivo data	1/1*	(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential	Table 1, 2
		confounders	9
		(b) Indicate number of participants with missing data for each	N/A
		(a) maleate number of participants with missing data for each	IN/A

		(c) Summarise follow-up time (eg, average and total amount)	N/A
Outcome data	15*	Report numbers of outcome events or summary measures over	Table 3a
		time	10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-	Table
		adjusted estimates and their precision (eg, 95% confidence	3a/b/c/d/e
		interval). Make clear which confounders were adjusted for and	Table 4
		why they were included	10-12
		(b) Report category boundaries when continuous variables were	3a/b/c/d/e
		categorized	7
		(c) If relevant, consider translating estimates of relative risk into	N/A
		absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and	N/A
		interactions, and sensitivity analyses	
Discussion			
Key results	10	Summarise key results with reference to study objectives	12
11cy 1 courts	18	Summarise key results with reference to study objectives	12

potential bias or imprecision. Discuss both direction and

Give a cautious overall interpretation of results considering

objectives, limitations, multiplicity of analyses, results from

Discuss the generalisability (external validity) of the study

Give the source of funding and the role of the funders for the

present study and, if applicable, for the original study on which

14-15

14-15

17

magnitude of any potential bias

the present article is based

similar studies, and other relevant evidence

variable of interest

results

20

21

22

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

Citation:

Interpretation

Generalisability

Other information

Funding

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008 Apr;61(4):344-9. PMID: 18313558

^{*}Give information separately for exposed and unexposed groups.